Business Wire

DIGITAL-ENVOY

14.7.2020 13:02:08 CEST | Business Wire | Press release

Share
Digital Envoy Appoints Jerrod Stoller as New President

Digital Envoy, the inventor of IP intelligence, today announced that Jerrod Stoller has been appointed as its new President. Current President and CEO Bill Calpin has stepped back from his role and has been named Chairman of the Board. Co-founder and Executive Vice President Rob Friedman assumes a dual role with the addition of the Vice-Chairman title.

Stoller will assume day-to-day leadership of Digital Envoy, overseeing operations for all three business units: Digital Element , Digital Resolve and Gathr Lab . His focus will be driving product innovation and market strategy across all three business units to align all offerings even closer with the needs of current customers and the marketplaces at large.

“The Digital Envoy team has accomplished great things since our start in 1999, and I am extremely proud of the growth and success our teams have achieved during that time,” said Calpin. “Our accomplishments have always been reliant on the entire team and the common goal of making Digital Envoy bigger and better. As Jerrod joins the team, all of us will continue to play key roles in helping our company maximise its potential. Based on his past experiences and successes, it’s easy to understand the enthusiasm our entire team has for Jerrod joining and leading our company into the future.”

Before joining Digital Envoy, Stoller was CEO of eVestment where he had directed the sales, marketing, client success and business development activities of the organisation globally for almost 10 years. He took on the CEO role 18 months ago, while retaining his other duties. Before joining eVestment, Stoller was the Regional Manager of RSA, the Security Division of EMC, where he directed company performance into triple-digit growth. Prior to RSA, he held leadership roles with Datalex Transportation Enterprise Software, Siemens Business Services, TransQuest Business Consulting and NCR. Stoller holds a bachelor’s degree in finance from Purdue University.

“I am thrilled to assume this new role and incredibly excited about what we can accomplish together for the future,” said Stoller. “There is tremendous opportunity ahead for Digital Envoy. I look forward to continuing to support our clients at the highest levels as well as innovating new market and product strategies within our industry niches to solve real-world problems.”

All changes are effective immediately.

“As Digital Envoy has continued to grow, we felt the need to expand the team to help focus on both the operational and strategic needs of the company,” said Friedman. “For Bill and I, our new roles provide opportunities to continue to stay engaged in the business while also providing us more time to address some of the longer-term opportunities and partnerships available to us as the markets continue to change.”

About Digital Envoy

Launched in 1999, Digital Envoy introduced the concept of privacy-sensitive IP-based geolocation and IP intelligence, allowing businesses—from ad networks to publishers to websites to retailers and more—to harness the power of location and new intelligence about connected users for a multitude of mission-critical applications. Taking more of a background role, in 2005 Digital Envoy introduced two divisions to help best address the unique needs of its diverse audience segments and business applications: Digital Element, which was created to continue the legacy of providing global geolocation data and services that bring anytime, anywhere relevance and context to online and mobile initiatives; and Digital Resolve, which was launched to deliver solutions that proactively secure online accounts, information, transactions and interactions from login to logout. In 2019, Digital Envoy launched Gathr Lab to further expand on its two decades of location data expertise and provide anonymous, custom audience insights and segments at scale, across all devices. By helping clients to reach, understand and amplify their best audiences, Gathr Lab is leading change by committing to data anonymity and refreshing transparency rooted in location-based data science. Visit www.digitalenvoy.com for more information.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye